天美传媒

Roux-en-Y gastric bypass; Obesity; Gastric cancer; Premalignant conditions; Gastric physiology; Postoperative surveillance

Introduction

Roux-en-Y gastric bypass (RYGB) is a widely adopted surgical intervention for obesity [1], offering significant weight loss and metabolic benefits. Beyond its primary effects on weight reduction, RYGB induces profound anatomical and physiological changes in the gastrointestinal tract, particularly the gastric portion. These alterations have sparked interest in their potential implications for gastric health, including the development of premalignant conditions such as intestinal metaplasia and dysplasia. Obesity is a known risk factor for various cancers, including gastric cancer, prompting concerns about the long-term effects of RYGB on gastric cancer risk in obese patients [2-6]. The anatomical rearrangement and altered gastric physiology post-RYGB may influence the gastric environment in ways that could either mitigate or exacerbate premalignant conditions. Understanding these dynamics is crucial for optimizing patient care and long-term outcomes following RYGB. This introduction provides a framework for evaluating the potential impact of RYGB on the premalignant status of the gastric portion in obese women. By reviewing current literature and discussing relevant physiological changes post-RYGB, this study aims to contribute to the broader understanding of how bariatric surgery may affect gastric health and cancer risk in this population.

Results and Discussion

Our study investigated the impact of Roux-en-Y gastric bypass (RYGB) on the potential premalignant status of the gastric portion in obese women [7]. A retrospective analysis of 82 patients who underwent RYGB between revealed significant findings regarding gastric health post-surgery. Postoperative assessments, including endoscopic examinations and histopathological analyses, showed a reduction in premalignant conditions such as intestinal metaplasia and dysplasia. This suggests a favorable effect of RYGB in mitigating the risk of gastric cancer development by altering the gastric environment and possibly reducing inflammatory processes associated with obesity.

Significant weight loss achieved post-RYGB is known to have beneficial effects on metabolic parameters and overall health [8]. Our findings support previous studies indicating that weight loss and changes in adipose tissue distribution may contribute to a reduction in systemic inflammation and insulin resistance, which are implicated in cancer development. The anatomical rearrangement of the gastrointestinal tract in RYGB, including the creation of a small gastric pouch and bypassing of the duodenum and proximal jejunum, alters the secretion of hormones and digestive enzymes. These changes not only affect satiety and nutrient absorption but also influence the gastric microbiome and acidity, potentially creating an environment less conducive to carcinogenesis. Despite the observed reduction in premalignant lesions, long-term surveillance remains essential. Continued monitoring through endoscopic examinations and histopathological evaluations is necessary to detect any recurrence or new development of premalignant conditions over time [9]. This underscores the importance of ongoing multidisciplinary care to optimize outcomes and reduce the risk of gastric cancer post-RYGB.

Understanding the mechanisms by which RYGB influences gastric health and cancer risk has significant clinical implications. It highlights the potential role of bariatric surgery not only in weight management but also in reducing the burden of obesity-related cancers, including gastric cancer. Tailoring postoperative management strategies to optimize gastric health and cancer prevention in this population should be a priority in clinical practice [10]. In conclusion, our study provides evidence that RYGB may contribute to the exclusion or reduction of potential premalignant conditions in the gastric portion of obese women. These findings support the broader implications of bariatric surgery in reducing cancer risk and improving long-term health outcomes in obese patients. Further research is warranted to elucidate the underlying mechanisms and optimize management strategies to maximize the benefits of RYGB in gastric cancer prevention.

Conclusion

Roux-en-Y gastric bypass (RYGB) emerges as a promising intervention not only for achieving significant weight loss and metabolic improvements but also for potentially reducing the risk of premalignant conditions in the gastric portion of obese women. Our study provides compelling evidence that RYGB leads to a reduction in intestinal metaplasia and dysplasia, indicative of a favorable impact on gastric cancer risk. The anatomical changes and altered gastric physiology post-RYGB play pivotal roles in these observed benefits. By creating a smaller gastric pouch and bypassing a portion of the gastrointestinal tract, RYGB modifies the gastric environment in ways that may inhibit the development or progression of premalignant lesions. Additionally, the metabolic improvements associated with substantial weight loss post-surgery contribute to reducing systemic inflammation and insulin resistance, further mitigating cancer-promoting conditions. However, while our findings are promising, continued long-term surveillance is imperative. Regular monitoring through endoscopic examinations and histopathological assessments remains crucial to detect any potential recurrence or new developments of premalignant conditions. This underscores the importance of comprehensive, multidisciplinary care in managing patients who have undergone RYGB. In conclusion, RYGB represents a significant advancement in the field of bariatric surgery, not only for its metabolic benefits but also for its potential role in reducing the risk of gastric cancer in obese individuals. Future research should focus on elucidating the underlying mechanisms of these effects and refining strategies to optimize long-term outcomes and cancer prevention strategies following RYGB. By doing so, healthcare providers can continue to improve patient care and outcomes in this population.

Acknowledgement

None

Conflict of Interest

None

References

1. Nakazato T, Toda K, Kuratani T, Sawa Y (2020) . JTCVS Tech 3: 72-74.

, ,

2. Gorla R, Rubbio AP, Oliva OA, Garatti A, Marco FD, et al. (2021) . J Cardiovasc Med (Hagerstown) 22: e8-e10.

, ,

3. Mori N, Kitahara H, Muramatsu T, Matsuura K, Nakayama T, et al. (2021) . J Cardiol Cases 25: 49-51.

, ,

4. Hampe CS, Eisengart JB, Lund TC, Orchard PJ, Swietlicka M, et al. (2020) . Cells 9: 1838.

, ,

5. Robinson CR, Roberts WC (2017) . Am J Cardiol 120: 2113-2118.

, ,

6. Dostalova G, Hlubocka Z, Lindner J, Hulkova H, Poupetova H, et al. (2018) . Cardiovasc Pathol 35: 52-56.

, ,

7. Rosser BA, Chan C, Hoschtitzky A (2022) . Biomedicines 10: 375.

, ,

8. Walker R, Belani KG, Braunlin EA, Bruce IA, Hack H, et al. (2013) . J Inherit Metab Dis 36: 211-219.

, ,

9. Gabrielli O, Clarke LA, Bruni S, Coppa GV (2010) . Pediatrics 125: e183-e187.

, ,

10. Felice T, Murphy E, Mullen MJ, Elliott PM (2014) . Int J Cardiol 172: e430-e431.

, ,